U.S. FDA Opposes Otsuka suit, Apotex Can Challenge Benicar Patents
This article was originally published in PharmAsia News
Executive Summary
FDA asks court to dismiss Otsuka’s Abilify suit; Apotex can seek infringement ruling on disclaimed Benicar patent; Apotex damages for omeprazole launch must be recalculated; hedge fund manager Kyle Bass files IPR petitions against Jazz and Shire.
You may also be interested in...
A Visual Guide To How FDA Can Manage The Pandemic
Our infographic illustrates the recommendations in FDA’s COVID-19 pandemic recovery and preparedness plan, ranging from strengthening the EUA process to managing the backlog of pending inspections.
Permanent Vaccine Facility Should Be On Standby For Future Pandemics, Moncef Slaoui Says
Operation Warp Speed confirmed the necessity of having a facility on hand to develop and manufacture a vaccine for the next crisis, the outgoing advisor says.
FDA’s COVID-19 Pandemic Plan Calls For Ongoing Clinical Trial Innovation
Broader use of adaptive trial designs and master protocols, checklist-based application review, and enhancement of real-world monitoring of products are among the recommendations of US FDA's COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) report, an effort months in making based on interviews with agency management, staff, and outside stakeholders.
Need a specific report? 1000+ reports available
Buy Reports